iECURE
Signal active
Organization
Contact Information
Overview
iECURE is a mutation-agnostic in vivo gene editing company striving to cure devastating diseases with high unmet needs.
About
Industries
Biotechnology, Genetics
Founded
2012
Employees
251-500
Headquarters locations
Philadelphia, Pennsylvania, United States, North America
Social
Profile Resume
iECURE headquartered in United States, North America, operates in the Biotechnology, Genetics sector. The company focuses on Biotechnology and has secured $1.8B in funding across 16 round(s). With a team of 251-500 employees, iECURE is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - iECURE, raised $65.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
2
Investors
4
Lead Investors
0
Total Funding Amount
$115.0M
Details
2
iECURE has raised a total of $115.0M in funding over 2 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2021 | Early Stage Venture | 50.0M | ||
| 2022 | Early Stage Venture | 65.0M |
Investors
iECURE is funded by 15 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Versant Ventures | - | FUNDING ROUND - Versant Ventures | 65.0M |
| Raymond Camahort | - | FUNDING ROUND - Raymond Camahort | 65.0M |
| iECURE | - | FUNDING ROUND - iECURE | 65.0M |
| Novo Holdings | - | FUNDING ROUND - Novo Holdings | 65.0M |
Recent Activity
News
May 29, 2024
The Business Journals - University of Pennsylvania gene-editing spinout iEcure hits the FDA trifecta
News
May 29, 2024
Business Wire - iECURE Receives FDA Fast Track Designation for ECUR-506 for the Treatment of Neonatal Onset Ornithine ...
News
May 17, 2024
The Business Journals - University of Pennsylvania gene-editing spinout iEcure hits the FDA trifecta
News
May 17, 2024
Business Journals - University of Pennsylvania gene-editing spinout iEcure hits the FDA trifecta
News
May 10, 2024
Yahoo Finance - iECURE Receives FDA Fast Track Designation for ECUR-506 for the Treatment of Neonatal Onset Ornithine ...
News
May 10, 2024
MarketWatch - Precision BioSciences Gets FDA Fast Track Designation for Program to Treat Genetic Urea Cycle Disorder in Newborns